Few IPOs Fighting the Biotech Tide

The thirteen biotech companies that have listed this year are hardly the poster children for good returns. But even after various haircuts and modest step-ups (the average pre-money step up for our group here is roughly 2.5) 2005's class has continued to suffer once public trading commences.